Heart Failure

REFER NOW

Heart Failure - Doctor Referral

Consent: Does the patient agree to this referral being submitted via the website? *

Yes

No (If not do not proceed)

Name *

Please enter Full Legal Name of the person being referred

First Name

Last Name

Phone Number *

Email Address

Best Contact Method * Please Select... Phone Email

Referred By

Name *

Practice *

Contact Number *

I have read and agree to the Terms and Conditions and Privacy Policy *

I agree

Thank you for your referring. We will contact you in our earliest convenience.

The purpose of this study is to investigate the safety and efficacy of empagliflozin versus placebo in patients with chronic heart failure with preserved ejection fraction.

Inclusion Criteria:

• Diagnosed with chronic heart failure (HF)

• Experiences shortness of breath when undertaking normal activities

• Echocardiogram in past 18 months with ejection fraction >40%

• Further inclusion criteria apply

Exclusion Criteria:

• Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1

• Implanted cardiac resynchronisation therapy

• Currently enrolled in another investigational device or drug study

• Currently taking SGLT-2 inhibitor or oral steroids

• Atrial Fibrillation > 110 bpm

• Systolic blood pressure > 180 mm Hg or < 100 mm Hg

• Requires dialysis

• Current or past history of malignancy within the past 2 years ( includes SCC)

• Further exclusion criteria apply

Further information can be found at https://clinicaltrials.gov/ct2/show/NCT03057951

---